Literature DB >> 9101117

Direct induction of complement activation by pharmacologic activation of plasminogen.

W T Schaiff1, P R Eisenberg.   

Abstract

BACKGROUND: Complement activation occurs in patients with myocardial infarction treated with fibrinolytic agents and plays a critical role in reperfusion injury. This study was designed to determine whether pharmacologic activation of plasminogen directly induces complement activations.
METHODS: Whole blood was incubated with plasminogen activators and the plasma was assayed for C3a levels as an indicator of complement activation.
RESULTS: Therapeutic concentrations of tissue-type plasminogen activator, streptokinase, or urokinase increased C3a concentrations from a baseline of approximately 500 ng/ml to an average of 1300-1500 ng/ml with tissue-type plasminogen activator or urokinase, and to an average of approximately 4000 ng/ml with streptokinase (P < 0.01, versus baseline for all plasminogen activators). Plasminogen activation also enhanced complement activation induced by conventional complement activators.
CONCLUSIONS: These results indicate that pharmacologic plasminogen activation may exacerbate reperfusion injury either by directly inducing complement activation or by enhancing the activation initiated by other mechanisms, or both.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101117     DOI: 10.1097/00019501-199701000-00002

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  12 in total

1.  Hypocomplementemia associated with macrophage activation syndrome in systemic juvenile idiopathic arthritis and adult onset still's disease: 3 cases.

Authors:  Mark Gorelik; Kathryn S Torok; Daniel A Kietz; Raphael Hirsch
Journal:  J Rheumatol       Date:  2011-02       Impact factor: 4.666

2.  Classical pathway complement activation on human endothelial cells.

Authors:  Wei Yin; Berhane Ghebrehiwet; Babette Weksler; Ellinor I Peerschke
Journal:  Mol Immunol       Date:  2006-12-14       Impact factor: 4.407

Review 3.  Combination approaches to potentiate immune response after photodynamic therapy for cancer.

Authors:  Tyler G St Denis; Kanza Aziz; Anam A Waheed; Ying-Ying Huang; Sulbha K Sharma; Pawel Mroz; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2011-04-09       Impact factor: 3.982

4.  Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.

Authors:  Martin O Judex; Barbara M Mueller
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

5.  The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.

Authors:  Jinan Li; Annelii Ny; Göran Leonardsson; Kutty Selva Nandakumar; Rikard Holmdahl; Tor Ny
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

6.  Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement.

Authors:  Andrew D Cook; Christine M De Nardo; Emma L Braine; Amanda L Turner; Ross Vlahos; Kerrie J Way; S Kaye Beckman; Jason C Lenzo; John A Hamilton
Journal:  Arthritis Res Ther       Date:  2010-03-02       Impact factor: 5.156

7.  Contaminated heparin associated with adverse clinical events and activation of the contact system.

Authors:  Takashi Kei Kishimoto; Karthik Viswanathan; Tanmoy Ganguly; Subbiah Elankumaran; Sean Smith; Kevin Pelzer; Jonathan C Lansing; Nammalwar Sriranganathan; Ganlin Zhao; Zoya Galcheva-Gargova; Ali Al-Hakim; Gregory Scott Bailey; Blair Fraser; Sucharita Roy; Thomas Rogers-Cotrone; Lucinda Buhse; Mark Whary; James Fox; Moheb Nasr; Gerald J Dal Pan; Zachary Shriver; Robert S Langer; Ganesh Venkataraman; K Frank Austen; Janet Woodcock; Ram Sasisekharan
Journal:  N Engl J Med       Date:  2008-04-23       Impact factor: 91.245

8.  Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysis.

Authors:  Katherine A Shuster; Shirley K Wrobleski; Angela E Hawley; Benedict R Lucchesi; Dorothy R Sorenson; Ingrid L Bergin; Robert E Sigler; Kenneth E Guire; Megan H Nowland; Thomas W Wakefield; Daniel D Myers
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

Review 9.  Platelet mediated complement activation.

Authors:  Ellinor I B Peerschke; Wei Yin; Berhane Ghebrehiwet
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

10.  Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.

Authors:  Yongzhi Guo; Jinan Li; Elin Hagström; Tor Ny
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.